

## Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies – Additional Resources

### **Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial**

Heerspink HJL, Radhakrishnan J, Alpers CE, et al; PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. *Lancet*. 2023;401(10388):1584-1594. doi:10.1016/S0140-6736(23)00569-X

Link: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(23\)00569-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00569-X/fulltext)

### **KDIGO 2021 clinical practice guideline for the management of glomerular diseases**

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. *Kidney Int*. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021

Link: [https://www.kidney-international.org/article/S0085-2538\(21\)00562-7/fulltext](https://www.kidney-international.org/article/S0085-2538(21)00562-7/fulltext)

### **Evaluating a new international risk-prediction tool in IgA nephropathy**

Barbour SJ, Coppo R, Zhang H, et al; International IgA Nephropathy Network. Evaluating a new international risk-prediction tool in IgA nephropathy. *JAMA Intern Med*. 2019;179(7):942-952. doi:10.1001/jamainternmed.2019.0600

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583088/>

### **Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group**

Trimarchi H, Barratt J, Cattran DC, et al; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. *Kidney Int*. 2017;91(5):1014-1021. doi:10.1016/j.kint.2017.02.003

Link: [https://www.kidney-international.org/article/S0085-2538\(17\)30101-1/fulltext](https://www.kidney-international.org/article/S0085-2538(17)30101-1/fulltext)

**Sparsentan: first approval**

Syed YY. Sparsentan: first approval. *Drugs*. 2023;83(6):563-568. doi:10.1007/s40265-023-01864-x

**Link:** <https://link.springer.com/article/10.1007/s40265-023-01864-x>